Global Celiac Disease Report 2016-2021: Treatment Options,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Global Celiac Disease Report 2016-2021: Treatment Options, Attributes, Market Positioning, Reimbursement Landscape & New Drug Pricing

Dublin, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Celiac Disease Drugs Price Analysis and Strategies - 2016" report to their offering. Celiac Disease Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Celiac Disease market. The research answers the following questions:

  • What are the key drugs marketed for Celiac Disease and their clinical attributes? How are they positioned in the Global Celiac Disease market?
  • What are the unit prices and annual treatment cost for Celiac Disease therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Celiac Disease drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Celiac Disease?

Research Scope:

  • Treatment Options - Identify key drugs marketed and prescribed for Celiac Disease including trade name, molecule name, and company
  • Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Celiac Disease
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Celiac Disease market
  • Celiac Disease Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
  • Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
  • Celiac Disease New Drug Pricing - Identify the effective pricing strategy for a new drug launch

Key Topics Covered: 1. Treatment Options 2. Drugs Clinical Attributes 3. Drugs Market Positioning 4. Drugs Price Analysis 5. Drugs Price Benchmarks 6. Drug Pricing & Reimbursement Landscape 7. Drugs Price Forecast 8. Market Unmet Needs 9. New Drug Pricing For more information about this report visit http://www.researchandmarkets.com/research/j9...ac_disease

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Immune Disorders Drugs, Gastrointestinal Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 487

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 292

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 445

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 233

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 466

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 403

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 425

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 328

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 378

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 237

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading

Top 5 Most Recently Viewed Articles

Turkish Stock Market Faces Decline Amid Sector Losses

Updated Category News Views 437

Turkish Stock Performance Overview The stock market in Turkey experienced a noticeable decline recently, driven primarily by losses in critical sectors such as Banking, Food & Beverages, and Basic Metals. These losses have contributed to an overall decrease in stock values, painting a challenging picture for investors. BIST 100 Index Decline At the close of trading, the...

Continue Reading
TaxDome Achieves Recognition in CPA Practice Advisor Awards

Updated Category News Views 161

TaxDome Triumphs in CPA Practice Advisor Efforts TaxDome, a leading practice management solution specially designed for tax professionals and accounting firms, has received outstanding recognition in the 2025 CPA Practice Advisor Readers' Choice Awards. Winning seven accolades and securing two runner-up positions, this achievement underscores the trust and esteem that the...

Continue Reading
Citi's Positive Outlook for Grab Holdings: A Buy Recommendation

Updated Category News Views 135

Citi Reaffirms Buy Rating on Grab Holdings Inc. In a recent note, Citi has reinforced its Buy rating on Grab Holdings Inc. (NASDAQ:GRAB), maintaining a price objective of $5.00. Analysts at Citi anticipate that Grab will announce its third-quarter results around mid-November. The firm prepared adjustments to International Financial Reporting Standards (IFRS) revenue and...

Continue Reading
Exploring Unusual Options Activity for American Airlines Group

Updated Category News Views 231

Insights into American Airlines Group's Options Activity In the bustling world of finance, American Airlines Group (NASDAQ: AAL) has drawn attention due to a notable surge in bullish options trading. Recently, our in-depth analysis unveiled a series of unusual trades that are shaping investor sentiment around American Airlines Group. Understanding the Options Activity The...

Continue Reading
CTERA Revolutionizes Hybrid Cloud Storage with MCP Support

Updated Category News Views 156

CTERA Leads the Way in Hybrid Cloud Innovations CTERA, the frontrunner in Enterprise Data Services, has recently announced an exciting advancement that positions it as a pioneer in hybrid cloud storage: the native support for the Model Context Protocol (MCP). This integration allows the hybrid cloud platform to embed an MCP Server, facilitating secure connections to...

Continue Reading